Study Reviews Use of Acadia’s Nuplazid as Treatment for Psychosis Linked to Parkinson’s Disease

Study Reviews Use of Acadia’s Nuplazid as Treatment for Psychosis Linked to Parkinson’s Disease
Acadia PharmaceuticalsNuplazid (pimavanserin) is a reliable treatment to manage hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), but its high cost and restricted access may limit its use in clinical practice, a new study says. The review, “Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis,” appeared in the journal Annals of Pharmacotherapy. Pimavanserin is a selective serotonin inverse ... read more
Source: Parkinson’s News TodayPublished on 2017-06-19By Joana Fernandes, PhD